文献速递药物相互作用治疗药物监测与药物基因组学

应用生理药动学模型指导美齐格多美I期药物相互作用研究的剂量选择

Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug-Drug Interaction Study.
PubMed 文献 · Clin Pharmacol Ther · 2025-10-07

美齐格多美(MEZI)是一种口服CELMoD™药物,体外主要经CYP3A4/5代谢并可能抑制P-gp和BCRP。本研究建立PBPK模型预测酶和转运体介导的药物相互作用,并据此设计I期临床试验,评估MEZI作为CYP3A诱导剂(利福平)和抑制剂(伊曲康唑)对象及作为转运体介导相互作用(地高辛、瑞舒伐他汀)促发剂。临床结果证实利福平使MEZI暴露降低93-95%,伊曲康唑使剂量归一化AUC增加约14倍,而MEZI对地高辛和瑞舒伐他汀血浆PK无临床意义影响。

要点

  • 利福平使MEZI暴露降低93-95%,伊曲康唑使剂量归一化AUC增加约14倍。
  • MEZI与地高辛或瑞舒伐他汀合用未引起底物血浆PK的临床有意义变化。
  • PBPK模型可前瞻性预测DDI并优化剂量选择、PK采样时间和洗脱期。

核心结论

  • PBPK模型成功预测MEZI与CYP3A调节剂的显著相互作用,临床结果证实利福平使MEZI暴露降低93-95%、伊曲康唑使剂量归一化AUC增加约14倍。
  • MEZI与P-gp和BCRP底物(地高辛、瑞舒伐他汀)合用未显示临床有意义的底物血浆PK变化,提示转运体介导的DDI可能性低。
  • 前瞻性PBPK模型经临床数据 refine 后提高了预测能力,支持对中/弱CYP3A调节剂的模拟。

研究设计与样本

  • 基于体外证据建立MEZI的PBPK模型,预测酶和转运体介导的DDI并指导I期临床DDI研究设计。
  • 开展PBPK指导的I期临床DDI研究,评估MEZI作为CYP3A诱导(利福平)和抑制(伊曲康唑)对象及作为转运体介导相互作用(地高辛、瑞舒伐他汀)促发剂。

主要发现

  • 利福平使MEZI的AUC降低93-95%。
  • 伊曲康唑使MEZI剂量归一化AUC增加约14倍。
  • 尽管MEZI暴露发生上述变化,MEZI仍耐受良好。
  • MEZI与地高辛或瑞舒伐他汀合用时,底物血浆PK无临床有意义变化。

关键数值与推荐

  • 利福平使MEZI的AUC降低93-95%。
  • 伊曲康唑使MEZI剂量归一化AUC增加约14倍。

临床怎么用

  • MEZI与强或中效CYP3A调节剂合用时需根据PBPK预测调整剂量策略。
  • MEZI与P-gp或BCRP底物(如地高辛、瑞舒伐他汀)合用时预计无需调整底物剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mezigdomide (MEZI) is an oral, highly potent CELMoD™ agent with promising antitumor and immune-stimulatory activity, optimized for Aiolos and Ikaros degradation. Preclinical evidence suggests MEZI is primarily metabolized by cytochrome P450 (CYP) 3A4/5 and has the potential to inhibit efflux transporters P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) in vitro. To predict the magnitude of enzyme- and transporter-mediated drug-drug interactions (DDI) and inform clinical study design, a physiologically based pharmacokinetic (PBPK) model was developed. A PBPK-informed Phase I clinical DDI study was conducted that evaluated MEZI as an object of CYP3A induction (rifampin) and inhibition (itraconazole) and as a precipitant of transporter-mediated interactions (digoxin and rosuvastatin). PBPK modeling predicted substantial interactions with strong and moderate CYP3A modulators, which informed a unique dose selection strategy, PK sampling time, and washout period. Clinical results confirmed reductions in MEZI exposure with rifampin (AUC reduced 93-95%) and increases with itraconazole (~14-fold for dose normalized AUC). MEZI was well-tolerated despite these changes in exposure. Additionally, coadministration of MEZI with P-gp and BCRP substrates, digoxin and rosuvastatin, showed no clinically meaningful changes in substrate plasma PK, indicating a low likelihood of significant transporter-mediated DDIs. The prospective PBPK model was refined with clinical data, improving predictions and supporting simulations for moderate/weak CYP3A modulators. This iterative "learn-confirm" approach underscores the utility of PBPK modeling in optimizing clinical trial design, ensuring participant safety, and anticipating DDI risks. The findings support MEZI's clinical development with informed dosing strategies, particularly for coadministration with CYP3A modulators.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Burnett J, Sychterz C, Katz J, et al. Application of Physiologically Based Pharmacokinetic Modeling to Inform Dose Selection of Mezigdomide in a Phase I Drug-Drug Interaction Study. Clin Pharmacol Ther. 2025. PMID: 41058119. doi:10.1002/cpt.70082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。